Skip to content
10-Q

Quarterly Report

AVENUE THERAPEUTICS, INC. ATXI

0001437749-25-034821

← back to feed
Filed
Nov 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 12, 2025 3.18M sh
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$979K
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$8.26M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $3.71M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $2.59M
Stockholders Equity Q3 2025 · Sep 30, 2025 $3.56M
Stockholders Equity Q3 2025 · Dec 31, 2024 $2.8M
Current Liabilities Q3 2025 · Sep 30, 2025 $1.42M
Current Liabilities Q3 2025 · Dec 31, 2024 $816K
Total Liabilities Q3 2025 · Sep 30, 2025 $1.42M
Total Liabilities Q3 2025 · Dec 31, 2024 $816K
Total Assets Q3 2025 · Sep 30, 2025 $3.73M
Total Assets Q3 2025 · Dec 31, 2024 $2.67M
Eps Basic Q3 2025 · Sep 30, 2025 −$0.21
Eps Basic Q3 2025 · Sep 30, 2025 −$0.71
Eps Basic Q3 2025 · Sep 30, 2024 −$1.92
Eps Basic Q3 2025 · Sep 30, 2024 −$17.27
Sga Expense Q3 2025 · Sep 30, 2025 $547K
Sga Expense Q3 2025 · Sep 30, 2025 $2.96M
Sga Expense Q3 2025 · Sep 30, 2024 $829K
Sga Expense Q3 2025 · Sep 30, 2024 $3.61M
Rd Expense Q3 2025 · Sep 30, 2025 $177K
Rd Expense Q3 2025 · Sep 30, 2025 $780K
Rd Expense Q3 2025 · Sep 30, 2024 $2.33M
Rd Expense Q3 2025 · Sep 30, 2024 $6.08M
Net Income Q3 2025 · Sep 30, 2025 −$683K
Net Income Q3 2025 · Sep 30, 2025 −$2.2M
Net Income Q3 2025 · Sep 30, 2024 −$3.08M
Net Income Q3 2025 · Sep 30, 2024 −$10.11M
Operating Income Q3 2025 · Sep 30, 2025 −$724K
Operating Income Q3 2025 · Sep 30, 2025 −$2.33M
Operating Income Q3 2025 · Sep 30, 2024 −$3.16M
Operating Income Q3 2025 · Sep 30, 2024 −$9.69M
Revenue Q3 2025 · Sep 30, 2025 $0
Revenue Q3 2025 · Sep 30, 2025 $1.4M
Revenue Q3 2025 · Sep 30, 2024 $0
Revenue Q3 2025 · Sep 30, 2024 $0